Histogenics Corporation (HSGX), a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace.
HSGX offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
HSGX has an exclusive channel collaboration agreement with Intrexon Corporation (XON) for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.
Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
November 26, 2019
RegMed Investors’ (RMi) closing bell: volume shapes the upside
November 25, 2019
RegMed Investors’ (RMi) closing bell: up, up and away
November 22, 2019
RegMed Investors’ (RMi) closing bell: a messy week ends on a positive note
November 21, 2019
RegMed Investors’ (RMi) closing bell: two out of four closes were negative this week so far as the IBB closed up +0.30% and the XBI closed up +0.16%
November 19, 2019
RegMed Investors’ (RMi) closing bell: the sector is showing strength
November 19, 2019
RegMed Investors’ (RMi) pre-open: what to BUY, who to SELL?
November 18, 2019
RegMed Investors’ (RMi) closing bell: resilience is not in the sector’s vocabulary
November 18, 2019
RegMed Investors’ (RMi) pre-open: indexes did point to a higher open
November 15, 2019
RegMed Investors’ (RMi) closing bell: indexes made fresh new highs as “our” universe got high on increasing value
35 companies, 1 interpreter!
Insight, foresight and recommendation
Histogenics (HSGX) -- Opened 2018 at $2.07, saw some ups at $2.92; opened February at $2.79 falling with a low of $2.50 to close 2/18 at $2.63.HSGX closed (1/25) its registered direct offering of 2,691,494 shares of its common stock, which includes 351,064 shares sold in connection with the exercise in full by the underwriter of its option to purchase additional shares. The total net proceeds of the offering are approximately $5.9 million after deducting the underwriting discounts and commissions with a solid book-running manager Canaccord Genuity. Another favorite ...
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors